Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A. Infants newly initiating HAART~* Less than 13 months of age~* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)~* Caregiver of infant plans to reside in Nairobi for at least 3 years (reported by caregiver)~* Caregiver is able to provide sufficient location information~B. Infants already receiving HAART~* Initiated HAART at \<13 months of age~* Records confirming HIV positive status~* Documentation of CD4% and weight prior to HAART initiation~* Must be on 1st line drug regimen~Eligibility for randomization:~* Completed 24 months of treatment with HAART~* Normalized growth: weight for height z-score (WHZ) \> -0.5; Child's weight must be above the 5th weight-for-age percentile and the weight curve must not be flat or falling (i.e. cross 2 major percentile lines or more over the past 3 months)~* CD4% \> 25~* Children who recently initiated or who require anti-tuberculosis treatment at the time of randomization will be ineligible for randomization.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 54 Months
- Healthy Volunteers: f

Study Arms:
- Interrupted HAART (Type: NO_INTERVENTION): After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
- Continued HAART (Type: ACTIVE_COMPARATOR): After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).